Comments
Commented by Juliane Zielonka on August 9th, 2024 | 06:30 CEST
Cardiol Therapeutics, Novo Nordisk, Bayer - Pharma stocks in focus
The healthcare sector promises further blockbusters for investors. Cardiol Therapeutics impresses with its promising Phase II study of CardiolRx™ for the treatment of the heart disease pericarditis. The growing market for pericarditis treatments offers the Company great potential, which has also been positively noted by analysts. The Danish company Novo Nordisk is experiencing impressive growth thanks to its GLP-1-based diabetes and obesity drugs. The active ingredient is causing a stir in the celebrity scene as an off-label weight loss injection, further boosting the Company's sales figures. Bayer AG is facing up to its challenges. Despite slight revenue growth in the second quarter of 2024, profits declined. Nevertheless, CEO Bill Anderson believes the Company is on the right track, particularly thanks to progress in the pharmaceutical pipeline. We have three companies in focus.
Read
Commented by Fabian Lorenz on August 8th, 2024 | 07:00 CEST
Siemens Energy tops, Evotec shocks, and what is causing the dynaCERT share to explode?
The Evotec share lost more than 35% yesterday. The share was already trading at a multi-year low before this drop. Investors were particularly shocked by the adjustment to the EBITDA forecast. Additionally, the biotech company indicated that it plans to downsize. This year, Siemens Energy has shown how quickly a difficult situation can be resolved. On the verge of bankruptcy at the end of 2023, it is back on track, although not thanks to renewable energies. In contrast, dynaCERT has yet to see its share price explode. A former Daimler manager will take the helm in the coming days and is expected to secure orders in Europe. Additionally, dynaCERT investors are waiting for VERRA certification.
Read
Commented by André Will-Laudien on August 7th, 2024 | 11:40 CEST
CRASH - AI and high-tech now on a silver platter! Amazon, LVMH, VCI Global, Cogia, A2Z Smart Technologies, and Super Micro Computer
Finally, a clear correction, say some; oh my goodness, say those who bought in recent weeks. The historical pattern is repeating itself. Attractive splits in the high-tech, followed by a new all-time high, and then the crash. Nvidia and especially the so-called "Magnificent Seven" have already had a first-class run with 100% returns in 2024. Now, the question is: can this euphoria be repeated? What is crucial now are also the cash reserves of traders and how much valuable capital has actually been lost in the recent collapse. US investment banks have done a quick calculation: USD 2.5 trillion in market capitalization was wiped out in just 48 hours. But as we know, money does not just disappear - it ends up somewhere else! We select interesting shares that offer more excitement at a reduced level!
Read
Commented by Fabian Lorenz on August 7th, 2024 | 08:05 CEST
Hydrogen sector receives EU billions: Nel, Plug Power, First Hydrogen share!
Governments love green hydrogen. The EU alone plans to spend over EUR 40 billion by 2030 to decarbonize the energy sector. This includes making steel production, heating operations, and combustion engines CO₂-neutral. Additionally, hydrogen can be used to store surplus renewable energy from solar and wind sources. When the Federal Audit Office recently criticized the slow expansion, the EU reaffirmed its targets. Therefore, the pace of expansion should be stepped up, and companies such as Nel and Plug Power - where tomorrow will be exciting - and First Hydrogen want to benefit from this. While the two heavyweights from Norway and the US are unable to get their losses under control and are still highly valued, the newcomer First Hydrogen may be entering the market at just the right time.
Read
Commented by Armin Schulz on August 6th, 2024 | 07:00 CEST
Barrick Gold, Prismo Metals, BASF - Precious metals as a safe haven in a crash
Last week, the indices recorded a noticeable decline on Thursday and Friday. The Fear and Greed Index is approaching a state of extreme fear, indicating that market sentiment is dominated by uncertainty and panic. In such times, investors often flee to safe havens, such as precious metals, while selling almost all other assets. This shift can lead to further turbulence on the markets and demonstrates how strongly emotions and risk behaviour influence events on the financial markets. We therefore take a closer look at two precious metal companies and analyse BASF, a stock that has been hit harder by the crash.
Read
Commented by Stefan Feulner on August 5th, 2024 | 07:15 CEST
BYD, Globex Mining, Coinbase - New opportunities after the price storm
Weak labour market data from the US, which once again increased fears of a recession, the Intel shock, and the further escalation of the situation in the Middle East, put additional pressure on stock markets around the globe. The Dow Jones fell by just under 3% over the week, while Germany's leading index, the DAX, lost over 4.5% in the same period. The market's overall weakness meant that positive company reports took a back seat. This creates opportunities at a discounted level.
Read
Commented by André Will-Laudien on August 5th, 2024 | 07:00 CEST
In the fight against cancer - 100% performance possible: Bayer, Vidac Pharma, Evotec, BioNTech and CureVac
The FED is giving new hope to the Biotech sector with lower interest rates, which are expected to happen as early as September. This is important for the near future, as share prices are lagging dramatically behind the NASDAQ performance in 2024. However, if extensive research can be financed under more favourable conditions, this should also help the stock market prices recover. The business models contain some good news, and selection is now crucial. We assist in selecting attractive stocks and provide entry levels.
Read
Commented by Juliane Zielonka on August 2nd, 2024 | 06:30 CEST
Transformation in full swing: Altech, Volkswagen, and Bayer focus on new technologies and markets
Shortly after the grandiose Olympic opening ceremony, Paris showed us what it means to sit in the dark. One day after the opening ceremony, the inhabitants of the Seine were hit by a power outage. Speculation as to the cause ranges from a cyber attack to sabotage, similar to the recent arson attacks on the French rail network. But one thing is certain, it shows how fragile the power supply currently is. This is reason enough for Altech Advanced Materials to press ahead with the development of its stationary solid-state battery. A type of local battery power plant ensures a stable power supply, even with fluctuations in the grid due to wind and solar energy. The German company has another profitable development up its sleeve for the EV market. Volkswagen continues to focus on its electric vehicles and can look forward to increased sales in China. Nevertheless, the Wolfsburg-based company must make considerable savings to remain profitable. The results of the first half of the year provide deep insights. Additionally, for 27 million women in the US, ones battery can be figuratively "empty" at times. Fatigue, hot flashes, and nervousness are classic symptoms of menopause. 27 million is the market size of menopausal women that Bayer AG now aims to capture with a very special medication...
Read
Commented by Juliane Zielonka on August 1st, 2024 | 07:45 CEST
Commodities, Travel, Defense: Almonty, Lufthansa, and Rheinmetall in focus
Global tensions offer enormous potential for investors. Given the conflicts with China and Russia, the US urgently needs to reorganise its supply chains for defense raw materials. Almonty Industries, for example, is gaining strategic importance for the US defense industry with its Sangdong project in South Korea. Meanwhile, German airline Lufthansa is struggling with price pressure and rising costs. The management is aware of the challenges and continues to pursue its strict turnaround strategy. Investors should be prepared for profit warnings here. Despite Russian threats, defense contractor Rheinmetall is expanding in Eastern Europe, with new projects in Hungary and Ukraine. Where is an investment currently proving lucrative?
Read
Commented by Fabian Lorenz on August 1st, 2024 | 06:30 CEST
Evotec slashed, Bayer sued, and Cardiol Therapeutics share praised
Anyone speculating on a quick rebound for Evotec will be disappointed. At present, one can at most speak of a bottoming out. It is fitting that a renowned analyst has slashed his price target for the German biotech share. Or is it only half as bad? Analysts see massive upside potential for the shares of Cardiol Therapeutics. The share price has more than doubled in the current year and is currently consolidating. There is an exciting entry opportunity now that positive study results have fizzled out on the stock market. Bayer, on the other hand, simply cannot get out of the world's courtrooms. In the US, a new lawsuit has been filed against the Leverkusen-based company; in another case, a multi-million dollar payment must be made.
Read